Pfizer 2026: The Reset Year
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immedi...
Fiscal Year: January - December
Pfizer Inc. (PFE), listed on the NYSE, has a market capitalization of $. As of Jan 05, 2026, the stock is trading at $25.18 per share, offering investors a clear view of its current market value. Pfizer Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 14.63, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Pfizer Inc. also offers a dividend yield of 6.83%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Pfizer Inc. (PFE) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Pfizer Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Pfizer Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Pfizer Inc. is 13.8, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Pfizer Inc. (PFE) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Pfizer Inc. (PFE) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Pfizer Inc. (PFE) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Pfizer Inc.. To access the full SS Score, consider upgrading your subscription.
Pfizer Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 14.63. Investors should compare these metrics with industry peers to gauge whether Pfizer Inc. is outperforming or underperforming within its sector.
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immedi...
Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework. An allocation of $2,670 distributed equally across three carefully ve...
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.
Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worryi...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, ...
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this month...
PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with...
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
CNBC's Annika Kim Constantino reports on Pfizer's 2026 guidance.
Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit o...
The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.
Pfizer expects revenue and earnings to fall in 2026.
Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a ...
Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its COVID products, sending its shares down 1.6% in premarket trading.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other compone...
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to hol...
The Dividend Harvesting Portfolio remains up 32.60% on invested capital, yielding 8.02%, despite a temporary dip in dividend income from the MSTY reverse split. A dovish Fed rate cut and bullish GDP p...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 14.17B | 44.12% | Est @44.1% |
| 2026 | 18.51B | 30.61% | Analyst x5 |
| 2027 | 18.28B | -1.27% | Analyst x6 |
| 2028 | 17.56B | -3.92% | Analyst x5 |
| 2029 | 16.27B | -7.36% | Analyst x5 |
| 2030 | 16.39B | 0.73% | Analyst x5 |
| 2031 | 16.16B | -1.40% | Est @-1.4% |
| 2032 | 16.12B | -0.25% | Est @-0.2% |
| 2033 | 16.21B | 0.56% | Est @0.6% |
| 2034 | 16.38B | 1.05% | Est @1.1% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 4.79B | 1.00 | 4.79B |
| 2024A | 9.84B | 1.00 | 9.84B |
| 2025E | 14.17B | 1.08 | 13.17B |
| 2026E | 18.51B | 1.16 | 15.98B |
| 2027E | 18.28B | 1.25 | 14.66B |
| 2028E | 17.56B | 1.34 | 13.09B |
| 2029E | 16.27B | 1.44 | 11.27B |
| 2030E | 16.39B | 1.55 | 10.55B |
| 2031E | 16.16B | 1.67 | 9.66B |
| 2032E | 16.12B | 1.80 | 8.96B |
| 2033E | 16.21B | 1.94 | 8.37B |
| 2034E | 16.38B | 2.08 | 7.86B |
| Terminal | 327.95B | 2.08 | 157.37B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.